JP2002542147A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002542147A5 JP2002542147A5 JP2000587755A JP2000587755A JP2002542147A5 JP 2002542147 A5 JP2002542147 A5 JP 2002542147A5 JP 2000587755 A JP2000587755 A JP 2000587755A JP 2000587755 A JP2000587755 A JP 2000587755A JP 2002542147 A5 JP2002542147 A5 JP 2002542147A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- inhibitor
- group
- phosphodiesterase
- associated therewith
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 description 79
- 239000012190 activator Substances 0.000 description 17
- 108091006146 Channels Proteins 0.000 description 15
- 208000015815 Rectal disease Diseases 0.000 description 15
- 239000003795 chemical substances by application Substances 0.000 description 15
- 229940099471 Phosphodiesterase inhibitor Drugs 0.000 description 11
- 239000000808 adrenergic beta-agonist Substances 0.000 description 10
- 239000002571 phosphodiesterase inhibitor Substances 0.000 description 9
- 239000000050 smooth muscle relaxant Substances 0.000 description 9
- 239000000262 estrogen Substances 0.000 description 8
- 229940011871 estrogen Drugs 0.000 description 8
- 102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 description 7
- 108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 description 7
- 239000003937 drug carrier Substances 0.000 description 7
- 239000000951 adrenergic alpha-1 receptor antagonist Substances 0.000 description 6
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 description 5
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 4
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000002840 nitric oxide donor Substances 0.000 description 4
- 239000002590 phosphodiesterase V inhibitor Substances 0.000 description 4
- 210000005070 sphincter Anatomy 0.000 description 4
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 3
- 239000002516 radical scavenger Substances 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 102000019197 Superoxide Dismutase Human genes 0.000 description 2
- 108010012715 Superoxide dismutase Proteins 0.000 description 2
- 239000000048 adrenergic agonist Substances 0.000 description 2
- 239000000674 adrenergic antagonist Substances 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000003301 hydrolyzing effect Effects 0.000 description 2
- 239000004036 potassium channel stimulating agent Substances 0.000 description 2
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical group CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
- NCGICGYLBXGBGN-UHFFFAOYSA-N 3-morpholin-4-yl-1-oxa-3-azonia-2-azanidacyclopent-3-en-5-imine;hydrochloride Chemical compound Cl.[N-]1OC(=N)C=[N+]1N1CCOCC1 NCGICGYLBXGBGN-UHFFFAOYSA-N 0.000 description 1
- 206010002153 Anal fissure Diseases 0.000 description 1
- 208000019751 Anorectal disease Diseases 0.000 description 1
- 208000016583 Anus disease Diseases 0.000 description 1
- 102000004654 Cyclic GMP-Dependent Protein Kinases Human genes 0.000 description 1
- 108010003591 Cyclic GMP-Dependent Protein Kinases Proteins 0.000 description 1
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
- 208000009531 Fissure in Ano Diseases 0.000 description 1
- 206010020852 Hypertonia Diseases 0.000 description 1
- 102000016924 KATP Channels Human genes 0.000 description 1
- 108010053914 KATP Channels Proteins 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 239000000006 Nitroglycerin Substances 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- HYHSBSXUHZOYLX-WDSKDSINSA-N S-nitrosoglutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CSN=O)C(=O)NCC(O)=O HYHSBSXUHZOYLX-WDSKDSINSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- RQFCJASXJCIDSX-UUOKFMHZSA-N guanosine 5'-monophosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O RQFCJASXJCIDSX-UUOKFMHZSA-N 0.000 description 1
- 229940039009 isoproterenol Drugs 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11232598P | 1998-12-14 | 1998-12-14 | |
| US60/112,325 | 1998-12-14 | ||
| US13991699P | 1999-06-17 | 1999-06-17 | |
| US60/139,916 | 1999-06-17 | ||
| US60/155,318 | 1999-09-12 | ||
| US15531899P | 1999-09-21 | 1999-09-21 | |
| PCT/US1999/029459 WO2000035434A2 (en) | 1998-12-14 | 1999-12-13 | Compositions and methods for the treatment of anorectal disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006328712A Division JP2007056042A (ja) | 1998-12-14 | 2006-12-05 | 肛門直腸障害の処置のための組成物および方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002542147A JP2002542147A (ja) | 2002-12-10 |
| JP2002542147A5 true JP2002542147A5 (enExample) | 2007-02-08 |
Family
ID=27381146
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000587755A Pending JP2002542147A (ja) | 1998-12-14 | 1999-12-13 | 肛門直腸障害の処置のための組成物および方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US6395736B1 (enExample) |
| EP (1) | EP1143956A3 (enExample) |
| JP (1) | JP2002542147A (enExample) |
| KR (1) | KR20010093828A (enExample) |
| CN (2) | CN1526448A (enExample) |
| AU (1) | AU764921B2 (enExample) |
| BR (1) | BR9916162A (enExample) |
| CA (1) | CA2354543A1 (enExample) |
| CZ (1) | CZ20012113A3 (enExample) |
| HU (1) | HUP0104676A3 (enExample) |
| IL (1) | IL143726A0 (enExample) |
| NO (1) | NO20012916L (enExample) |
| PL (1) | PL348817A1 (enExample) |
| WO (1) | WO2000035434A2 (enExample) |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9801398D0 (en) | 1998-01-22 | 1998-03-18 | Anggard Erik E | Chemical compounds |
| US6627632B2 (en) * | 1998-12-14 | 2003-09-30 | Cellegy Pharmaceuticals, Inc. | Compositions and methods for the treatment of anorectal disorders |
| GB9924636D0 (en) * | 1999-10-18 | 1999-12-22 | Norgine Bv | Laxative preparation |
| HRP20020751B1 (hr) | 2000-02-15 | 2011-01-31 | Sugen | Pirolom supstituirani 2-indolinoni kao inhibitori protein kinaze |
| MXPA03000931A (es) * | 2000-07-31 | 2004-08-12 | Cellegy Pharma Inc | Composiciones y metodos para el tratamientos de trastornos anorectales. |
| GB0020588D0 (en) * | 2000-08-21 | 2000-10-11 | Pfizer Ltd | Treatment of wounds |
| AU2000270300A1 (en) * | 2000-09-13 | 2002-03-26 | Isis Innovation Limited | Use of phosphodiesterase inhibitors for the treatment of anorectal disorders |
| AR042586A1 (es) * | 2001-02-15 | 2005-06-29 | Sugen Inc | 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa |
| DE10118305A1 (de) * | 2001-04-12 | 2002-10-17 | Bayer Ag | Zusammensetzungen zur nasalen Applikation |
| DE10118306A1 (de) * | 2001-04-12 | 2002-10-17 | Bayer Ag | Imidazotriazinonhaltige Zusammensetzungen zur nasalen Applikation |
| EP2351765A3 (en) * | 2001-07-10 | 2012-02-22 | Lakewood-Amedex, Inc | Oligonucleotide-containing pharmacological compositions and their use |
| WO2003022239A2 (en) * | 2001-09-07 | 2003-03-20 | Western Holdings Llc | Stable water in oil aminophylline emulsions |
| JP2005508953A (ja) | 2001-10-10 | 2005-04-07 | スージェン・インコーポレーテッド | キナーゼ阻害剤としての３−［４−（置換ヘテロサイクリル）−ピロール−２−イルメチリデン］−２−インドリノン誘導体 |
| JP4563679B2 (ja) * | 2001-12-06 | 2010-10-13 | デューク ユニバーシティ | 形成外科における組織弁壊死の予防 |
| WO2003075851A2 (en) * | 2002-03-06 | 2003-09-18 | Cellegy Pharmaceuticals, Inc. | Compositions and methods for the treatment of anorectal disorders |
| WO2003088961A1 (en) | 2002-04-19 | 2003-10-30 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Beta-agonist compounds comprising nitric oxide donor groups and reactive oxygen species scavenger groups and their use in the treatment of respiratory disorders |
| US20040147534A1 (en) * | 2003-01-23 | 2004-07-29 | Foote Mary Ann | Topical composition and method for treating occlusive wounds |
| US6863825B2 (en) | 2003-01-29 | 2005-03-08 | Union Oil Company Of California | Process for removing arsenic from aqueous streams |
| US7220422B2 (en) * | 2003-05-20 | 2007-05-22 | Allergan, Inc. | Methods and compositions for treating eye disorders |
| US7799832B2 (en) * | 2003-10-23 | 2010-09-21 | Valeant Pharmaceuticals North America | Combinations of retigabine and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains |
| DE10352132A1 (de) * | 2003-11-04 | 2005-06-09 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmazeutische Zusammensetzung aus einem Beta-3-Adrenozeptor-Agonisten und einem Alpha Agonisten |
| US20060147504A1 (en) * | 2004-12-30 | 2006-07-06 | Bobby Corry | Feminine anti-itch cloth |
| US8252308B2 (en) * | 2005-01-27 | 2012-08-28 | C.B. Fleet Company Inc. | Feminine anti-itch gel |
| WO2006084913A2 (en) * | 2005-02-11 | 2006-08-17 | Nolabs Ab | Device for treatment of rectal disorders, and manufacturing process for the same, involving nitric oxide |
| AU2006334020B2 (en) | 2005-12-30 | 2012-07-05 | Mor Research Applications Ltd. | Device and method for treating the anal sphincter |
| WO2007081521A2 (en) * | 2006-01-05 | 2007-07-19 | Essentialis, Inc. | Salts of potassium atp channel openers and uses thereof |
| US7960436B2 (en) * | 2006-06-05 | 2011-06-14 | Valeant Pharmaceuticals International | Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and-2,3-dihydro-1H-indenes as potassium channel modulators |
| US20080045534A1 (en) * | 2006-08-18 | 2008-02-21 | Valeant Pharmaceuticals North America | Derivatives of 1,3-diamino benzene as potassium channel modulators |
| US8993593B2 (en) * | 2006-08-23 | 2015-03-31 | Valeant Pharmaceuticals International | N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators |
| NZ575652A (en) * | 2006-08-23 | 2011-08-26 | Valeant Pharmaceuticals Int | Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators |
| US8722929B2 (en) * | 2006-10-10 | 2014-05-13 | Valeant Pharmaceuticals International | N-[2-amino-4-(phenylmethoxy)phenyl] amides and related compounds as potassium channel modulators |
| KR20090083479A (ko) * | 2006-11-28 | 2009-08-03 | 밸리언트 파마슈티컬즈 인터내셔널 | 칼륨 채널 조절제로서의 1,4 디아미노 이환 레티가빈 유사체 |
| US8066874B2 (en) | 2006-12-28 | 2011-11-29 | Molycorp Minerals, Llc | Apparatus for treating a flow of an aqueous solution containing arsenic |
| US8367684B2 (en) * | 2007-06-13 | 2013-02-05 | Valeant Pharmaceuticals International | Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators |
| US8563566B2 (en) | 2007-08-01 | 2013-10-22 | Valeant Pharmaceuticals International | Naphthyridine derivatives as potassium channel modulators |
| US7786146B2 (en) * | 2007-08-13 | 2010-08-31 | Valeant Pharmaceuticals International | Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators |
| US8349764B2 (en) | 2007-10-31 | 2013-01-08 | Molycorp Minerals, Llc | Composition for treating a fluid |
| US8252087B2 (en) | 2007-10-31 | 2012-08-28 | Molycorp Minerals, Llc | Process and apparatus for treating a gas containing a contaminant |
| WO2010146591A2 (en) | 2009-06-18 | 2010-12-23 | Rdd Pharma Ltd. | Methods and devices for delivery of pharmaceutical agents within orifices of the body |
| US8778969B2 (en) * | 2009-11-07 | 2014-07-15 | Peter H Proctor | Nitrone, nitroso, and nitroxide spintraps and spin labels and their hydroxylamines |
| DK2512479T3 (en) * | 2009-12-18 | 2016-06-06 | Exodos Life Sciences Ltd Partnership | Compositions for the treatment of peripheral vascular disease |
| CN102145004B (zh) * | 2010-02-09 | 2012-03-21 | 鲁南制药集团股份有限公司 | 己酮可可碱在制备预防或治疗功能性便秘的药物中的用途 |
| EP2558101A4 (en) * | 2010-04-15 | 2013-09-18 | Univ Mcgill | TOPICAL TREATMENTS OF PAIN |
| US9233863B2 (en) | 2011-04-13 | 2016-01-12 | Molycorp Minerals, Llc | Rare earth removal of hydrated and hydroxyl species |
| US9743857B2 (en) | 2011-12-16 | 2017-08-29 | The Regents Of The University Of California | Digital manometry finger-mountable sensor device |
| CN103393690B (zh) * | 2013-08-01 | 2016-05-11 | 南通大学附属医院 | Katp通道开放剂在制备治疗术后疼痛药物中的应用 |
| WO2015112588A1 (en) | 2014-01-22 | 2015-07-30 | Biomimetix Jv, Llc | Methods of treating skin disorders |
| WO2015112586A1 (en) * | 2014-01-22 | 2015-07-30 | Duke University | Methods of treating pruritus |
| MX370462B (es) | 2014-03-07 | 2019-12-13 | Secure Natural Resources Llc | Oxido de cerio (iv) con propiedades de remocion de arsenico excepcionales. |
| RU2595799C1 (ru) * | 2015-05-14 | 2016-08-27 | Светлана Николаевна Суслина | Композиция для лечения анальных трещин в форме крема |
| WO2017168174A1 (en) | 2016-04-02 | 2017-10-05 | N4 Pharma Uk Limited | New pharmaceutical forms of sildenafil |
| EP3801460B1 (en) * | 2018-06-01 | 2025-03-12 | Tavanta Therapeutics Hungary Incorporated | Topical amlodipine salts for the treatment of anorectal diseases |
| TWI886158B (zh) | 2019-10-10 | 2025-06-11 | 加拿大商再諾製藥公司 | 選擇性鉀通道調節劑之固態晶型 |
| CA3155812A1 (en) | 2019-11-08 | 2021-05-14 | Cynthia Louise HARDEN | Methods of treating depressive disorders |
| TW202245744A (zh) | 2021-02-09 | 2022-12-01 | 加拿大商再諾製藥公司 | 治療失樂症之方法及用途 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4117249C2 (de) * | 1991-05-27 | 1998-05-14 | Christian Dr Stief | Linsidomin zur Behandlung erektiler Dysfunktionen |
| GB9119467D0 (en) * | 1991-09-12 | 1991-10-23 | Smithkline Beecham Corp | Chemical compounds |
| US5234947A (en) * | 1991-11-07 | 1993-08-10 | New York University | Potassium channel activating compounds and methods of use thereof |
| ZA941027B (en) * | 1993-02-16 | 1994-11-11 | Smithkline Beecham Corp | Chemical compounds |
| WO1994022460A1 (en) * | 1993-04-05 | 1994-10-13 | University Patents, Inc. | Diagnosis and treatment of erectile dysfunction |
| US5948762A (en) * | 1993-07-16 | 1999-09-07 | Schering Aktiengesellschaft | Treatment of uterine contractility disorders with a nitric oxide synthase substrate and/or donor or a nitric oxide inhibitor |
| WO1995006466A1 (en) * | 1993-09-01 | 1995-03-09 | Koren Laboratories Pty. Limited | Treatment of anorectal disorders |
| PT719145E (pt) * | 1994-05-27 | 2001-01-31 | Cellegy Pharma Inc | Composicao dadora de oxido nitrico para tratamento de desordens anais |
| US5994294A (en) * | 1996-02-02 | 1999-11-30 | Nitromed, Inc. | Nitrosated and nitrosylated α-adrenergic receptor antagonist compounds, compositions and their uses |
| US5932538A (en) * | 1996-02-02 | 1999-08-03 | Nitromed, Inc. | Nitrosated and nitrosylated α-adrenergic receptor antagonist compounds, compositions and their uses |
| CA2270118A1 (en) * | 1996-11-01 | 1998-05-14 | Nitromed Inc. | Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses |
| DE69735552T3 (de) * | 1996-12-23 | 2009-08-13 | S.L.A. Pharma Ag | Pharmazeutische zubereitung zur behandlung der analinkontinenz und analem juckreiz |
| CN1298309A (zh) * | 1998-02-27 | 2001-06-06 | 同步神经元有限责任公司 | 治疗肛门区疼痛的方法及其组合物 |
| ES2205945T3 (es) * | 1998-10-23 | 2004-05-01 | Pfizer Inc. | Pirazolopirimidinonas inhibidoras de gmpc pde5 para el tratamiento de disfunciones sexuales. |
-
1999
- 1999-12-13 US US09/460,306 patent/US6395736B1/en not_active Expired - Fee Related
- 1999-12-13 CA CA002354543A patent/CA2354543A1/en not_active Abandoned
- 1999-12-13 CN CNA200410008292XA patent/CN1526448A/zh active Pending
- 1999-12-13 HU HU0104676A patent/HUP0104676A3/hu unknown
- 1999-12-13 AU AU21763/00A patent/AU764921B2/en not_active Ceased
- 1999-12-13 IL IL14372699A patent/IL143726A0/xx unknown
- 1999-12-13 CN CNB998144304A patent/CN1149983C/zh not_active Expired - Fee Related
- 1999-12-13 PL PL99348817A patent/PL348817A1/xx unknown
- 1999-12-13 WO PCT/US1999/029459 patent/WO2000035434A2/en not_active Ceased
- 1999-12-13 EP EP99966154A patent/EP1143956A3/en not_active Withdrawn
- 1999-12-13 CZ CZ20012113A patent/CZ20012113A3/cs unknown
- 1999-12-13 BR BR9916162-1A patent/BR9916162A/pt not_active Application Discontinuation
- 1999-12-13 JP JP2000587755A patent/JP2002542147A/ja active Pending
- 1999-12-13 KR KR1020017007394A patent/KR20010093828A/ko not_active Ceased
-
2001
- 2001-01-23 US US09/769,621 patent/US20010012856A1/en not_active Abandoned
- 2001-06-13 NO NO20012916A patent/NO20012916L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5554381A (en) | Low flux matrix system for delivering potent drugs transdermally | |
| Burnett | The role of nitric oxide in erectile dysfunction: implications for medical therapy | |
| Goldenberg | Safety and efficacy of sildenafil citrate in the treatment of male erectile dysfunction | |
| US6987129B2 (en) | Compounds and methods for the treatment of urogenital disorders | |
| Lecci et al. | Pharmacological validation of a novel animal model of anticipatory anxiety in mice | |
| US4885154A (en) | Method for reducing sensitization or irritation in transdermal drug delivery and means therefor | |
| JP2005504721A5 (enExample) | ||
| JP2002542147A (ja) | 肛門直腸障害の処置のための組成物および方法 | |
| JP2002531488A (ja) | 揮発性液体薬剤を送出するための経皮パッチ | |
| Park et al. | A neuroprotective role of extracellular signal-regulated kinase in N-acetyl-O-methyldopamine-treated hippocampal neurons after exposure to in vitro and in vivo ischemia | |
| US20030212139A1 (en) | Methods, compositions, and kits for enhancing female sexual desire and responsiveness | |
| WO2003077925A1 (en) | Sulfatase inhibiting continuous progestogen contraceptive regimens | |
| TW201922232A (zh) | 右旋美索芬(dextromethorphan)經皮輸送裝置 | |
| Horowski et al. | Prolactin-lowering effect of low doses of lisuride in man | |
| Fain et al. | Regulation of leptin release and lipolysis by PGE2 in rat adipose tissue | |
| WO2004096118B1 (en) | Composition for improving cognition and memory | |
| Bucher et al. | Vasoconstrictor effects of various melatonin analogs on the rat tail artery in the presence of phenylephrine | |
| Rillema et al. | Studies on the possible role of protein kinase C in the prolactin regulation of cell replication in Nb2 node lymphoma cells | |
| Fernández–guasti et al. | 8-OH-DPAT and male rat sexual behavior: partial blockade by noradrenergic lesion and sexual exhaustion | |
| US5478568A (en) | Butyrophenone transdermal compositions | |
| van Harten et al. | Single‐and multiple‐dose nisoldipine kinetics and effects in the young, the middle‐aged, and the elderly | |
| Montiel et al. | Distinct protein kinases regulate SNAP‐25 expression in chromaffin cells | |
| Lin et al. | Involvement of tyrosine kinase in the pyrogenic fever exerted by NOS pathways in organum vasculosum laminae terminalis | |
| Philip et al. | Differential role of PTK, ERK and p38 MAPK in superoxide impairment of NMDA cerebrovasodilation | |
| MD3119C2 (ro) | Formă medicamentoasă pentru administrare orală cu eliberarea prelungită a molsidominei |